Re:Cognition Health

We are excited to watch "Alzheimer's: A Turning Point?" on Panorama, BBC One on Monday 12th February at 8pm. This follows the journey of volunteers participating in clinical trials, some from Re:Cognition Health's UK centres, testing new-generation medications designed to slow down the progression of the #disease. #alzheimersdisease #alzheimersresearch #clinicaltrials #alzheimerstreatment https://lnkd.in/dFdG4_Jz

Could Ozempic help treat #depression and #Alzheimer's? Consultant Neurologist Dr Steve Allder weighs in on the #ozempic conversation. Read the full article on the The Independent: https://lnkd.in/eTYf4HZa

Delighted to see Re:Cognition Health clinical trials volunteer Mr Mike Colley proudly sharing his journey with the The Telegraph, where he says “The new Alzheimer’s drug has given me my life back”. Mr Colley was diagnosed with Alzheimer’s in 2021 at Re:Cognition Health. He was enrolled onto a #clinicaltrial testing #Donanemab, a new-generation medication designed to slow the progression of the disease by targeting and removing #amyloid plaque from the brain. Read the full story: https://lnkd.in/eDyATQwP We are so grateful to all of our incredible volunteers and study partners who participate in clinical trials every year, helping to find new medications to treat the disease. Together we are making a profound difference to the future of Alzheimer's. For further information and opportunities about clinical trials visit https://lnkd.in/ea5tfwnk

Today, on Clinical Trials Day 2024, we honour the remarkable contributions of clinical trials in the fight against #Alzheimersdisease. Clinical trials are the backbone of medical advancements, providing the essential research needed to develop new treatments and therapies that can change lives. Hundreds of thousands of people in the UK and USA volunteer to participate in clinical trials every year. Clinical trials are not just conducted to test medicine, they are also used to test and compare different medical treatments, products and equipment such as surgical tools, diagnostic machines,  wound dressings and mental health therapies.   Participating in a clinical trial has numerous benefits for volunteers, who are helping to develop new treatments and playing an active role in #research; importantly, volunteers are benefiting future generations,  as well as taking control of their own health. Thank you to our #team at Re:Cognition Health, all of our amazing #volunteers, study partners, scientists and everyone who contributes to clinical trials; together we are making a positive difference to create a future without Alzheimer's. #ClinicalTrialsDay #CTD2024 #AlzheimersResearch #MedicalAdvancements #HealthcareInnovation #ClinicalTrials #FightAlzheimers #ResearchMatters #PatientCare #FutureofMedicine

We were thrilled to have experts from Re:Cognition Health speak at the @Head_First_LLP conference at the Royal College of Physicians today! Dr Emer MacSweeney, our CEO, Founder and Consultant Neuroradiologist, shared fascinating insights on how brain imaging reveals the intricate connections between the brain and body. Dr Steve Allder, our Consultant Neurologist, discussed the practical application of evidence in brain injury treatment, highlighting the interplay between the brain, body, environment and social relationships. #BrainHealth #Neurology #BrainImaging #BrainInjury #HealthcareInnovation #education

Re:Cognition Health is proud to be delivering trials for a groundbreaking vaccine targeting toxic brain proteins to prevent Alzheimer's. As reported in the Sunday Express by lucy johnston, which featured insights from Dr Emer MacSweeney, Re:Cognition Health’s CEO and Medical, successful results could offer hope within five years. The trial aims to halt Alzheimer's progression by clearing harmful proteins. If successful, it could revolutionise dementia prevention, sparing millions from the devastation of this disease.   The ACI-AD study involves a vaccine that triggers the body's immune system to attack and break down #amyloid plaques, which are associated with #Alzheimer's disease. Unlike typical immune responses that can cause #inflammation, this vaccine is designed to avoid activating inflammatory T cells.   Read the full article: https://lnkd.in/eCaxHe8t For further information about this trial visit 0800 802 1030 email [email protected] or visit https://lnkd.in/e3gwxxJw #alzheimersprevention #alzheimersresearch

Dr Tom MacLaren, Consultant #psychiatrist at Re:Cognition Health, spoke with Healthline Media about a recent Swedish study that suggests a lower mortality risk among those taking #ADHD #medications, especially for unnatural causes. The study followed 150,000 individuals for 11 years and revealed a significant correlation between medication use and reduced mortality rates. Dr MacLaren suggests that the study's findings might motivate individuals with ADHD to consider medication and focus on their overall #health. While the exact link between medication and lower mortality remains unclear, managing #ADHDsymptoms can indirectly improve physical health, #selfcare, and potentially mitigate risks associated with substance use. Read the full article: https://lnkd.in/ekCMVEaj?

Our CEO and Medical Director Dr Emer MacSweeney was featured in the Independent speaking about #diagnosticbloodtests for #Alzheimer's which could be on the horizon. These tests could detect the disease up to 20 years before symptoms manifest, paving the way for early intervention through opportunities in #clinicaltrials, testing new-generation medications to slow disease progression. Clinical trials are currently the only way in the UK to access these medications. #alzheimersdiagnosis #alzheimersresearch https://lnkd.in/eBaRxGRG

Consultant Neurologist Dr Steve Allder discussed the common causes of difficulty swallowing (#dysphagia) with the Independent. Dr Allder explains some of the #neurological problems such as #stroke, #Parkinson’s and #amyotrophiclateralsclerosis (ALS) which can lead to dysphagia and stresses the importance of seeking #medical attention if experiencing any symptoms. Read the full article: https://lnkd.in/em8CVG5W #neurology #expertcomment #earlydiagnosis #londonclinic

We have some exciting news! The Re:Cognition Health UK and US site networks are proud to be preferred sites within the PPD Select Partnership Program of Thermo Fisher Scientific’s PPD clinical research business, a global leader in clinical research. We're excited about the opportunities this relationship brings, and we are looking forward to working with the PPD Strategic Site Collaborations team and evolving our relationship within the PPD Select Program, across our existing ten sites.    #PPD #clinicalresearch #clinicaltrials #Alzheimersresearch #Neurologyresearch #clinicalexcellence #partnership #collaboration #globalleader